Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLuxembourg Institute of Health

About this trial

This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change.

At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol.

The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data.

The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.

Eligibility criteria

Qualifiers

≥ 18 years old

Participants are willing and able to comply with the protocol including undergoing data and sample collection as well as study visits and examinations.

Signed informed consent form

Diagnosed with Inflammatory bowel disease, either Crohn's disease or ulcerative colitis, at least 3 months before the enrolment AND occurrence of a significant change in the treatment of the disease (either change of drug dosage OR change of medication within the same treatment class OR change of treatment class OR addition of a drug to a treatment regimen already ongoing). A change of drug dosage or frequency is considered significant if it fulfills the requirements in section 7.1 Note: Patients with ostomy or with short bowel syndrome can be included if they fulfill all the eligibility criteria

Disqualifiers

Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits (such as mental disability that makes it difficult or impossible to answer questionnaires)

Not fluent in any of the following languages: French, English or German

Known pregnancy

Trial design

Treatments tested in this trial

  • All participants will be asked to provide data and samples for collection and analysis.

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

Luxembourg Institute of Health

Lead sponsor

Luxembourg National Research Fund

Collaborator

Centre Hospitalier du Luxembourg

Collaborator

Hôpitaux Robert Schuman

Collaborator

University of Luxembourg

Collaborator